Entera Bio Ltd. ENTX
3.24 USD -0.01 (-0.31%)
At closeNov 10, 2026, 4:00 PM EST
3.24 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
3.17 Day range 3.25
1.00 52-week range 3.92
- YTD
- +67.01%
- 1 year
- +8.00%
News
benzinga.com Entera Bio Q3 EPS $(0.11) Misses $(0.07) Estimate Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 57.14 percent decrease over losses of…
globenewswire.com Entera Announces Third Quarter 2026 Financial Results and Business Updates Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
globenewswire.com Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of…
benzinga.com Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5…
globenewswire.com Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
benzinga.com Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
globenewswire.com Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional…
globenewswire.com Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of…
benzinga.com Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11 Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
benzinga.com Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.- benzinga.com Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9 Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
benzinga.com Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
benzinga.com Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures mixed; Oxford Industries fell 12.6% after mixed results. Lululemon, Guidewire, Asana and UiPath also dropped premarket.
globenewswire.com Correction: Entera to Participate in Upcoming Fall Investor Conferences TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief…
globenewswire.com Entera to Participate in Upcoming Fall Investor Conferences TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief…
benzinga.com Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
globenewswire.com Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens…
marketbeat.com Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled…
globenewswire.com Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with…
globenewswire.com Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase…
globenewswire.com Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company's Chief…
prnewswire.com Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd.
benzinga.com Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk Entera Bio Ltd. (NASDAQ:ENTX) shares traded higher Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
benzinga.com Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consumer staples up 2%, tech down 1.9%. Durable goods orders rise 0.3%.
benzinga.com Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.
globenewswire.com Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for…
zacks.com Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
globenewswire.com Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regular session. The market value of their outstanding shares is at $4.0 million. Aditxt (NASDAQ:ADTX) shares…
globenewswire.com Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to…- benzinga.com Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected…
globenewswire.com Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected…
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED) Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures rose on Monday following Friday’s sharp sell-off. Futures of the major…
benzinga.com Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilitiesThe companies have accelerated this program and aim to…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…- benzinga.com Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the…
- benzinga.com Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
benzinga.com Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.- benzinga.com Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.